Michael Barbella, Managing Editor12.05.22
A team of Northwell Health clinicians, electrophysiologists and clinical trial investigators at The Feinstein Institutes for Medical Research have successfully implanted a modular cardiac rhythm management (CRM) system in the first patient enrolled in Boston Scientific Corp.'s MODULAR ATP clinical trial. The patient—James Giambrone, 56, of Amityville, N.Y.—is the first person to be part of the clinical trial in the Northeast and was implanted with an implantable defibrillator and leadless pacemaker.
Giambrone was admitted to NSUH’s emergency department in late September, citing chest pains, an elevated heartbeat, and sweating. After a barrage of tests, treatments and a three-day medically induced coma, Giambrone was asked to participate in the clinical trial.
“I almost died. If Dr. Epstein and the entire team of nurses and doctors didn’t do what they did as quickly as they did, I wouldn’t be here today,” Giambrone said. “I am beyond grateful for what they have done for me. This has taught me the importance of listening to your body and taking care of yourself – don’t wait until the last literal minute.”
Implanted at North Shore University Hospital (NSUH), the trial will evaluate the efficacy of communication between devices within the Boston Scientific mCRM Modular Therapy System—the EMBLEM MRI Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER Modular Pacing System (MPS). The trial will also investigate the system and procedure-related complication-free rate of the EMPOWER MPS. These devices are designed for people who are at risk for sudden cardiac arrest and are intended to communicate with each other wirelessly. Working together, the EMPOWER MPS will help maintain a person’s regular heart rhythm. If needed, the S-ICD, which provides protection without touching the heart or substernal space, is designed to deliver a shock to restore normal functioning—much like a paramedic might deliver to someone suffering a heart attack.
“We are pleased to participate in this important study and enroll our first patient that will help evaluate the effectiveness of the mCRM Modular Therapy System and potentially expand the patient population that can benefit from S-ICD therapy,” said Laurence M. Epstein, M.D., system director of electrophysiology at Northwell and trial administrator. “Positive outcomes from this trial may one day give physicians the added flexibility to provide a new option for patients who develop pacing needs while preserving many of the benefits S-ICD therapy.”
The S-ICD is a proven treatment option for the prevention of sudden cardiac death. Because it provides protection without touching the heart, it eliminates many complications associated with leads placed in those locations. The leadless pacemaker, which looks like a small capsule, is attached to the inside of the lower right chamber of the heart. After the surgery, Giambrone was out of the hospital and back to work within days. The MODULAR ATP trial will enroll up to 60 centers in the United States, Canada, and Europe up to 300 patients.
“About 450,000 Americans die each year from cardiac arrest, the most common cause of death. Clinicians and patients must have the most effective preventative treatments on-hand,” said Christina Brennan, M.D., senior vice president of clinical research at the Feinstein Institutes. “Clinical trials are key to gathering critical information that can lead to the approval and adoptions of those treatments.”
The Feinstein Institutes for Medical Research is the home of Northwell Health, the largest healthcare provider and private employer in New York state. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes has five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine.
Giambrone was admitted to NSUH’s emergency department in late September, citing chest pains, an elevated heartbeat, and sweating. After a barrage of tests, treatments and a three-day medically induced coma, Giambrone was asked to participate in the clinical trial.
“I almost died. If Dr. Epstein and the entire team of nurses and doctors didn’t do what they did as quickly as they did, I wouldn’t be here today,” Giambrone said. “I am beyond grateful for what they have done for me. This has taught me the importance of listening to your body and taking care of yourself – don’t wait until the last literal minute.”
Implanted at North Shore University Hospital (NSUH), the trial will evaluate the efficacy of communication between devices within the Boston Scientific mCRM Modular Therapy System—the EMBLEM MRI Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER Modular Pacing System (MPS). The trial will also investigate the system and procedure-related complication-free rate of the EMPOWER MPS. These devices are designed for people who are at risk for sudden cardiac arrest and are intended to communicate with each other wirelessly. Working together, the EMPOWER MPS will help maintain a person’s regular heart rhythm. If needed, the S-ICD, which provides protection without touching the heart or substernal space, is designed to deliver a shock to restore normal functioning—much like a paramedic might deliver to someone suffering a heart attack.
“We are pleased to participate in this important study and enroll our first patient that will help evaluate the effectiveness of the mCRM Modular Therapy System and potentially expand the patient population that can benefit from S-ICD therapy,” said Laurence M. Epstein, M.D., system director of electrophysiology at Northwell and trial administrator. “Positive outcomes from this trial may one day give physicians the added flexibility to provide a new option for patients who develop pacing needs while preserving many of the benefits S-ICD therapy.”
The S-ICD is a proven treatment option for the prevention of sudden cardiac death. Because it provides protection without touching the heart, it eliminates many complications associated with leads placed in those locations. The leadless pacemaker, which looks like a small capsule, is attached to the inside of the lower right chamber of the heart. After the surgery, Giambrone was out of the hospital and back to work within days. The MODULAR ATP trial will enroll up to 60 centers in the United States, Canada, and Europe up to 300 patients.
“About 450,000 Americans die each year from cardiac arrest, the most common cause of death. Clinicians and patients must have the most effective preventative treatments on-hand,” said Christina Brennan, M.D., senior vice president of clinical research at the Feinstein Institutes. “Clinical trials are key to gathering critical information that can lead to the approval and adoptions of those treatments.”
The Feinstein Institutes for Medical Research is the home of Northwell Health, the largest healthcare provider and private employer in New York state. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes has five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine.
